Godalming, UK, 31 May 2007: In line with the Transparency Directive's transitional provision 6, Sinclair Pharma plc (LSE: SPH) would like to notify the market of the following: The Company's issued share capital at 30 April 2007 consists of 93,421,219 ordinary shares with a nominal value of 1 pence per share, with voting rights (one vote per ordinary share). The Company does not hold any ordinary shares in Treasury. Therefore, the total number of ordinary shares in the Company with voting rights is 93,421,219. The above figure of 93,421,219 ordinary shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Service Authority's Disclosure and Transparency Rules. For further information please contact: Sinclair Pharma plc Tel: +44 (0) 1483 410 600 Dr Michael Flynn, CEO Zoe McDougall, Director of Communications Capital MS&L Mary Clark, Halina Kukula Tel +44 (0)20 7307 5340 Notes to Editors: About Sinclair Pharma Plc Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. ---END OF MESSAGE---